News and Announcements
Invitation to Invest in Australia’s Most Exciting Cannabis Company
- Published March 20, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Recently the Founder of the Oz Medicann Group (OMG), John Leith launched the Series B capital raise with a cash injection of $600k. With increased revenues this financial year OMG will move from Early Stage Innovation to accelerated Growth. OMG’s impressive track record of bringing products to market, building brand awareness and customer loyalty and market ready innovative products will ensure future success and expansion into the global market.
OMG’s unique offering brings together patient centred health care, wellness and education. As an investor you will see the rewards of an integrated model which offers a number of revenue streams and opportunities in international markets. OMG has a diversified distribution model with over 3000 on line members, on-line sales and products in 350+ stockists across Australia.
Invest before June 30, 2020 to ensure that you maximise your investment through the ESIC Incentive program.
About Oz Medicann
OMG is a licenced patient-centric medicinal cannabis and hemp wellness company with a key focus on research, product development, education, cultivation and GMP standard manufacturing.
OMG is a diversified portfolio of companies comprising Oz Medicann Pharma, Educann and Hemp Oz and is supported by a team of medical practitioners, business leaders, marketing, sales and distribution expertise and innovation in new medicine.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
